C3 Complement Inhibitor AMY-101

Preferred Label : C3 Complement Inhibitor AMY-101;

NCIt synonyms : C3 Inhibitor AMY-101;

NCIt related terms : AMY-101;

NCIt definition : A compstatin-based inhibitor of human complement component C3, with potential use as a treatment for various diseases in which excessive complement activation plays a key role, including paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 glomerulopathy (C3G). Upon administration, C3 complement inhibitor AMY-101 selectively binds to C3 and inhibits C3 activity. This prevents complement pathway activation, and inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. C3 is a crucial and central component of the complement system, and the complement system is an integral component of the innate immune response.;

UNII : 4Z4DFR9BX7;

InChIKey : MUSGYEMSJUFFHT-UWABRSFTSA-N;

CAS number : 1427001-89-5;

Molecule name : AMY 101; AMY-101;

NCI Metathesaurus CUI : CL1407729;

Details

Origin ID

C173801;

UMLS CUI

C5139735;

Currated CISMeF NLP mapping
- AMY-101 [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- AMY-101 [MeSH Supplementary Concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients